Genetic discrimination in life insurance is a long-standing issue in Australia. In July 2019, an industry self-regulated moratorium removed the equirement for Australian consumers to disclose genetic test results to life insurance companies on policies up to A$500,000. Although the moratorium is an important step, concerns remain around the financial limits, terms, public awareness, lack of government oversight and compliance monitoring. The impact and adequacy of the moratorium needs evaluation to inform the planned 2022 review. A new research project has been funded by the MRFF Genomic Health Futures Mission, which aims to monitor the efficacy of the moratorium.
|Number of pages||10|
|Journal||Medical Journal of Australia|
|Publication status||Accepted/In press - 12 Aug 2020|